Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Burney Co.

Burney Co. decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,202 shares of the biopharmaceutical company's stock after selling 19,536 shares during the period. Burney Co.'s holdings in Alnylam Pharmaceuticals were worth $1,675,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. SYM FINANCIAL Corp grew its stake in Alnylam Pharmaceuticals by 5.3% in the 1st quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock worth $274,000 after buying an additional 51 shares in the last quarter. Allianz Asset Management GmbH lifted its holdings in shares of Alnylam Pharmaceuticals by 100.7% in the 1st quarter. Allianz Asset Management GmbH now owns 218,503 shares of the biopharmaceutical company's stock worth $59,000,000 after acquiring an additional 109,632 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Alnylam Pharmaceuticals by 9.2% during the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock valued at $161,000 after buying an additional 50 shares during the last quarter. Allegiance Financial Group Advisory Services LLC raised its holdings in Alnylam Pharmaceuticals by 39.6% during the 1st quarter. Allegiance Financial Group Advisory Services LLC now owns 1,353 shares of the biopharmaceutical company's stock valued at $365,000 after buying an additional 384 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $2,268,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a report on Monday, June 30th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Finally, UBS Group lifted their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $347.75.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Up 0.2%

NASDAQ:ALNY traded up $0.81 during mid-day trading on Friday, reaching $328.81. The company's stock had a trading volume of 666,674 shares, compared to its average volume of 911,887. The firm has a market capitalization of $42.87 billion, a PE ratio of -157.33 and a beta of 0.23. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The stock has a fifty day moving average of $310.69 and a 200-day moving average of $274.03. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.16) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.